Chen ST, Maruthur NM, Appel LJ
References in the comments-- #Pharmacy #Hypertension #FutureOfMedicine #ClinicalTrials #Biotech #RNAi #Cardiology #HealthcareInnovation To view or add a comment, sign in In episode 12 of Wicked Good Cardiometabolic Chat, powered by Drug Topics, pharmacy and diabetes experts Jennifer D Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, and Hailey Choi, PharmD, BCACP, CDCES, break down the most impactful diabetes technology updates emerging from the 2026 American Diabetes Association (ADA) Scientific Sessions
These unregulated products may contain impurities, incorrect dosages, or contaminants that pose serious health risks
If someone struggles with GLP-1 side effects, knowing that Mazdutide lacks GIP activation might explain why they tolerate it better than tirzepatide while still experiencing glucagons metabolic benefits